BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TAK-188 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TAK-188\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07205718-11367@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20281226
DTEND;VALUE=DATE:20281227
SUMMARY:TAK-188: Phase 1/2 readout est. (NCT07205718)
DESCRIPTION:TAK-188\, phase 1/2.\nStudy: A Study of TAK-188 in Adults With 
 Advanced or Spreading Solid Tumors\nEstimated primary completion: 26 Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tak-188#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0720571
 8
URL:https://assetmemo.bio/drug/tak-188#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
